Pharmacotherapy of acne

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 6, 2008, Pages 955-971

  Degitz, Klaus ^a,b   Ochsendorf, Falk ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Department of Dermatology and Venerology ^*  (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Acne; Androgens; Azelaic acid; Benzoyl peroxide; Follicular hyperkeratosis; Propionibacteria; Retinoids; Salicylic acid; Seborrhoea; Systemic therapy; Tetracyclins; Topical therapy

Indexed keywords

ADAPALENE; AZELAIC ACID; AZITHROMYCIN; BENZOYL PEROXIDE; CLINDAMYCIN; COTRIMOXAZOLE; CYTOCHROME P450 1A1; DAPSONE; DOXYCYCLINE; ERYTHROMYCIN; FLUTAMIDE; ISOTRETINOIN; LYMECYCLINE; MACROLIDE; MINOCYCLINE; NADIFLOXACIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; PREDNISONE; RETINOIC ACID; RETINOID; ROXITHROMYCIN; SALICYLIC ACID; STEROID 21 MONOOXYGENASE; TAZAROTENE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; UNINDEXED DRUG; ZINC;

ABDOMINAL CRAMP; ABNORMAL LABORATORY RESULT; ACNE; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIBIOTIC RESISTANCE; AUTOIMMUNE HEPATITIS; BEDTIME DOSAGE; BIRTH DEFECT; BLOATING; BONE PAIN; CANDIDIASIS; CARDIOVASCULAR DISEASE; CHLOASMA; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORNEA OPACITY; DARIER DISEASE; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; ENTERITIS; ERYTHEMA; ESOPHAGITIS; ESOPHAGUS ULCER; EYE DISEASE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; HEADACHE; HEMOLYSIS; HEPATITIS; HUMAN; HYPERPIGMENTATION; HYPERTRICHOSIS; HYPOPIGMENTATION; INFLAMMATION; LIP DISEASE; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; METHEMOGLOBINEMIA; MICROBIAL COLONIZATION; MONOTHERAPY; MYALGIA; NAUSEA; NIGHT BLINDNESS; NONHUMAN; OSTEOPHYTE; OSTEOPOROSIS; PANCREATITIS; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHOTOTOXICITY; PROPIONIBACTERIUM; PSEUDOMEMBRANOUS COLITIS; REVIEW; SEBORRHEA; SIDE EFFECT; SKIN ABRASION; SKIN BURNING SENSATION; SKIN DISEASE; SKIN IRRITATION; SKIN PRURITUS; SKIN REDNESS; SKIN TINGLING; STEVENS JOHNSON SYNDROME; TERATOGENICITY; TOXIC HEPATITIS; VAGINA CANDIDIASIS; VOMITING; WEIGHT GAIN;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; BENZOYL PEROXIDE; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HUMANS; RETINOIDS;

EID: 42649116458     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.6.955     Document Type: Review

References (158)

1. Plewig G, Kligman AM. Acne and Rosacea. Berlin: Springer; 2000
2. Gollnick HP, Cunliffe WJ. Management of acne. A report from a global alliance to improve outcomes in acne. J Am A-cad Dermatol 2003;49:S1-38
3. Bowe WP, Leyden JJ, Crerand CE, et al. Body dysmorphic disorder symptoms among patients with acne vulgaris. J Am Acad Dermatol 2007;57(2):222-30
4. Herane MI, Ando I. Acne in infancy and acne genetics. Dermatology 2003;206:24-8
5. Degitz K, Placzek M, Borelli C, Plewig G. Pathophysiology of acne. J Dtsch Dermatol Ges 2007;5(4):316-23
6. Zouboulis CC, Degitz K. Androgen action on human skin - from basic research to clinical significance. Exp Dermatol 2004;13(Suppl 4):5-10
7. Leyden J, Bergfeld W, Drake L, et al. A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris. J Am Acad Dermatol 2004;50(3):443-7
8. Zouboulis CC, Bohm M. Neuroendocrine regulation of sebocytes - a pathogenetic link between stress and acne. Exp Dermatol 2004;13(Suppl 4):31-5
9. Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol 1996;106:176-82
10. Burkhart CG, Burkhart CN. Expanding the microcomedone theory and acne therapeutics: Propionibacterium acnes biofilm produces biological glue that holds corneocytes together to form plug. J Am Acad Dermatol 2007;57(4):722-4
11. Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol 1975;65(4):382-4
12. Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002;169(3):1535-41
13. Webster GF. Overview over the pathogenesis of acne. In: Acne and its Therapy. Webster GF, et al. editors. New York: Informa; 2007. p. 1-7
14. Jappe U, Ingham E, Henwood J, Holland KT. Propionibacterium acnes and inflammation in acne; P. acnes has T-cell mitogenic activity. Br J Dermatol 2002;146(2):202-9
15. Mouser PE, Baker BS, Seaton ED, Chu AC. Propionibacterium acnes-reactive T helper-1 cells in the skin of patients with acne vulgaris. J Invest Dermatol 2003;121(5):1226-8
16. Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003;121:20-7
17. Zouboulis CC, Nestoris S, Adler YD, et al. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol 2003;139(5):668-70
18. Cordain L, Lindeberg S, Hurtado M, et al. Acne vulgaris: a disease of Western civilization. Arch Dermatol 2002;138:1584-90
19. Adebamowo CA, Spiegelman D, Berkey CS, et al. Milk consumption and acne in adolescent girls. Dermatol Online J 2006;12(4):1
20. Smith RN, Mann NJ, Braue A, et al. A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial. Am J Clin Nutr 2007;86(1):107-15
21. Lehmann HP, Robinson KA, Andrews JS, et al. Acne therapy: a methodologic review. J Am Acad Dermatol 2002;47(2):231-40
22. Draelos ZK. Patient compliance: enhancing clinician abilities and strategies. J Am Acad Dermatol 1995;32(5 Pt 3):S42-8
23. Baldwin HE. Tricks for improving compliance with acne therapy. Dermatol Ther 2006;19(4):224-36
24. Ozolins M, Eady EA, Avery A, et al. Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. Health Technol Assess (Winchester, England) 2005;9(1):iii-212
25. Piacquadio D, Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance. J Am Acad Dermatol 1998;39(2 Pt 3):S67-73
26. Petkovich M, Brand NJ, Krust A, Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987;330(6147):444-50
27. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990;345(6272):224-9
28. Marcelo CL, Madison KC. Regulation of the expression of epidermal keratinocyte proliferation and differentiation by vitamin A analogs. Arch Dermatol Res 1984;276(6):381-9
29. Stadler R, Muller R, Detmar M, Orfanos CE. Retinoids and keratinocyte differentiation in vitro. Dermatologica 1987;175(Suppl 1):45-55
30. Lavker RM, Leyden JJ, Thorne EG. An ultrastructural study of the effects of topical tretinoin on microcomedones. Clin Ther 1992;14(6):773-80
31. Roos TC, Jugert FK, Merk HF, Bickers DR. Retinoid metabolism in the skin. Pharmacol Rev 1998;50(2):315-33
32. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998;139(Suppl 52):48-56
33. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis Cutan Med Pract 1999;63(6):349-54
34. Lucky A, Jorizzo JL, Rodriguez D, et al. Efficacy and tolerance of adapalene cream 0.1% compared with its cream vehicle for the treatment of acne vulgaris. Cutis Cutan Med Pract 2001;68(4 Suppl):34-40
35. Chalker DK, Lesher JL Jr, Smith JG Jr, et al. Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation. J Am Acad Dermatol 1987;17(2 Pt 1):251-4
36. Leyden JJ, Tanghetti EA, Miller B, et al. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1% microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis Cutan Med Pract 2002;69(2 Suppl):12-9
37. Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis Cutan Med Pract 2001;67(6 Suppl):4-9
38. Webster GF, Guenther L, Poulin YP, et al. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis Cutan Med Pract 2002;69(2 Suppl):4-11
39. Leyden J, Lowe N, Kakita L, Draelos Z. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis Cutan Med Pract 2001;67(6 Suppl):10-6
40. Dominguez J, Hojyo MT, Celayo JL, et al. Topical isotretinoin vs. topical retinoic acid in the treatment of acne vulgaris. Int J Dermatol 1998;37(1):54-5
41. Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol 2002;147(3):523-7
42. Van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol 1998;11 (Suppl 1):S13-19, discussion S19-28
43. Jensen BK, McGann LA, Kachevsky V, Franz TJ. The negligible systemic availability of retinoids with multiple and excessive topical application of isotretinoin 0.05% gel (Isotrex) in patients with acne vulgaris. J Am Acad Dermatol 1991;24(3):425-8
44. Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol 2000;43(2 Pt 3):S31-5
45. Navarre-Belhassen C, Blanchet P, Hillaire-Buys D, et al. Multiple congenital malformations associated with topical tretinoin. Ann Pharmacother 1998;32(4):505-6
46. Camera G, Pregliasco P. Ear malformation in baby born to mother using tretinoin cream. Lancet 1992;339(8794):687
47. Autret E, Berjot M, Jonville-Bera AP, et al. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy Lancet 1997;350(9074):339
48. Caron GA. Tretinoin and pregnancy. Lancet 1993;341(8861):1664
49. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet 1993;341(8854):1181-2
50. Nacht S, Gans EH, McGinley KJ, Kligman AM. Comparative activity of benzoyl peroxide and hexachlorophene. In vivo studies against Propionibacterium acnes in humans. Arch Dermatol 1983;119(7):577-9
51. Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol 1995;132(2):204-8
52. Gans EH, Kligman AM. Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibacterium acnes. J Dermatol Treat 2002;13(3):107-10
53. Waller JM, Dreher F, Behnam S, et al. 'Keratolytic' properties of benzoyl peroxide and retinoic acid resemble salicylic acid in man. Skin Pharmacol Physiol 2006;19(5):283-9
54. Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol 1998;39(2 Pt 3):S17-24
55. Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol 2003;4(7):473-92
56. Pierard GE, Pierard-Franchimont C, Goffin V. Digital image analysis of microcomedones. Dermatology (Basel, Switzerland) 1995;190(2):99-103
57. Swinyer LJ, Baker MD, Swinyer TA, Mills OH Jr. A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. Br J Dermatol 1988;119(5):615-22
58. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004;292(6):726-35
59. Morelli R, Lanzarini M, Vincenzi C, Reggiani M. Contact dermatitis due to benzoyl peroxide. Contact Dermat 1989;20(3):238-9
60. Dreno B. Topical antibacterial therapy for acne vulgaris. Drugs 2004;64(21):2389-97
61. Eady EA, Cove JH, Joanes DN, et al. Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of the literature on their clinical benefit and comparative efficacy. J Dermatol Treat 1990;1:215-26
62. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005;153(2):395-403
63. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant?: implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003;4(12):813-31
64. Ochsendorf FR. Clinical relevance of antibiotic resistance in acne. G Ital Dermatol Venereol 2006;141:183-6
65. Barza M, Goldstein JA, Kane A, et al. Systemic absorption of clindamycin hydrochloride after topical application. J Am Acad Dermatol 1982;7(2):208-14
66. Stoughton RB, Cornell RC, Gange RW, Walter JF. Double-blind comparison of topical 1 percent clindamycin phosphate (Cleocin T) and oral tetracycline 500 mg/day in the treatment of acne vulgaris. Cutis Cutan Med Pract 1980;26(4):424-5, 429
67. Becker LE, Bergstresser PR, Whiting DA, et al. Topical clindamycin therapy for acne vulgaris. A cooperative clinical study. Arch Dermatol 1981;117(8):482-5
68. Milstone EB, McDonald AJ, Scholhamer CF Jr. Pseudomembranous colitis after topical application of clindamycin. Arch Dermatol 1981;117(3):154-5
69. Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol 1986;122(5):583-4
70. Igarashi K, Ishitsuka H, Kaji A. Comparative studies on the mechanism of action of lincomycin, streptomycin, and erythromycin. Biochem Biophys Res Commun 1969;37:499-504
71. Jacobs MR, Appelbaum PC. Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Expert Opin Pharmacother 2006;7(14):1957-66
72. Graupe K, Cunliffe WJ, Gollnick HP, Zaumseil RP. Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis Cutan Med Pract 1996;57(1 Suppl):20-35
73. Cunliffe WJ, Holland KT. Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Dermatol Venereol 1989;143(Suppl):31-4
74. Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Dermatol Venereol Suppl (Stockh) 1989;143:439-47
75. Hjorth N, Graupe K. Azelaic acid for the treatment of acne. A clinical comparison with oral tetracycline. Acta Dermatol Venereol Suppl (Stockh) 1989;143:45-8
76. Davies M, Marks R. Studies on the effect of salicylic acid on normal skin. Br J Dermatol 1976;95(2):187-92
77. Kaminsky A. Less common methods to treat acne. Dermatology (Basel, Switzerland) 2003;206(1):68-73
78. Gross G. Benzoyl peroxide and salicylic acid therapy. In: Acne and its Therapy. Webster G, et al. editors. New York: Informa Healthcare; 2007. p. 117-35
79. Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007;56(3):439, e431-410
80. Thiboutot DM, Willmer J, Sharata H, et al. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. Clin Pharmacokinet 2007;46(8):697-712
81. Charakida A, Charakida M, Chu AC. Double-blind, randomized, placebo-controlled study of a lotion containing triethyl citrate and ethyl linoleate in the treatment of acne vulgaris. Br J Dermatol 2007;157(3):569-74
82. Leyden JJ, Hickman JG, Jarratt MT, et al. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001;5(1):37-42
83. Ellis CN, Leyden J, Katz HI, et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis Cutan Med Pract 2001;67(2 Suppl): 13-20
84. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997;37(4):590-5
85. Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002;24(7):1117-33
86. Bowman S, Gold M, Nasir A, Vamvakias G. Comparison of clindamycin/ benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. J Drugs Dermatol 2005;4(5):611-8
87. Burkhart CG, Burkhart CN. Treatment of acne vulgaris without antibiotics: tertiary amine - benzoyl peroxide combination vs. benzoyl peroxide alone (Proactiv Solution). Int J Dermatol 2007;46(1):89-93
88. Wolf JE Jr, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003;49(3 Suppl):S211-7
89. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006;54(1):73-81
90. Thiboutot DM, Weiss J, Bucko A, et al. Adapalene-Benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007;57:791-9
91. Korkut C, Piskin S. Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. J Dermatol 2005;32(3):169-73
92. Campbell JL Jr, Weiss JS. The results of the MORE trial: overview. Cutis Cutan Med Pract 2006;78(1 Suppl):5-11
93. Tanghetti E, Abramovits W, Solomon B, et al. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial. J Drugs Dermatol 2006;5(3):256-61
94. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed 2005;4(3):138-46
95. Leyden J, Thiboutot DM, Shalita AR, et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol 2006;142(5):605-12
96. Zhang JZ, Li LF, Tu YT, Zheng J. A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. J Dermatol Treat 2004;15(6):372-8
97. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 2006;142(5):597-602
98. Alirezai M, George SA, Coutts I, et al. Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol 2007;17(1):45-51
99. Brinkmeier T, Frosch PJ. Orale antibiotika mit antiinflammatorischer/ immunmodulatorischer wirkung für die therapie verschiedener dermatosen. Hautarzt 2002;53:456-65
100. Jain A, Sangal L, Basal E, et al. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J 2002;8:2
101. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54(2):258-65
102. Lehmann HP, Andrews JS, Robinson KA, et al. Management of Acne. Rockville, MD: Agency for Healthcare Research and Quality; 2001
103. Dreno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol 2004;14(6):391-9
104. Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: efficacy and safety (Cochrane Review). In: The Cochrane Library, issue 3 edition. Oxford: Update Software; 2002
105. Ochsendorf F. Systemic antibiotic therapy of acne vulgaris. J Dtsch Dermatol Ges 2006;4(10):828-41
106. Fleischer AB Jr, Dinehart S, Stough D, Plott RT. Safety and efficacy of a new extended-release formulation of minocycline. Cutis Cutan Med Pract 2006;78(4 Suppl):21-31
107. Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 2002;46:917-23
108. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003;139(4):459-64
109. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007;56(5):791-802
110. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dental Res 1998;12(2):12-26
111. Akamatsu H, Nishijima S, Akamatsu M, et al. Clinical evaluation of roxithromycin in patients with acne. J Int Med Res 1996;24(1):109-14
112. Ferahbas A, Utas S, Aykol D, et al. Clinical evaluation of roxithromycin: a double-blind, placebo-controlled and crossover trial in patients with acne vulgaris. J Dermatol 2004;31(1):6-9
113. Parsad D, Pandhi R, Nagpal R, Negi KS. Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. J Dermatol 2001;28(1):1-4
114. Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol 2005;30(3):215-20
115. Cotterill JA, Cunliffe WJ, Forster RA, et al. A comparison of trimethoprim-sulphamethoxazole with oxytetracycline in acne vulgaris. Br J Dermatol 1971;84(4):366-9
116. Bottomley WW, Cunliffe WJ. Oral trimethoprim as a third-line antibiotic in the management of acne vulgaris. Dermatology (Basel, Switzerland) 1993;187(3):193-6
117. Cunliffe WJ, Aldana OL, Goulden V. Oral trimethoprim: a relatively safe and successful third-line treatment for acne vulgaris. Br J Dermatol 1999;141(4):757-8
118. Cunliffe WJ. Evolution of a strategy for the treatment of acne. J Am Acad Dermatol 1987;16:591-9
119. Layton AM, Hughes BR, Hull SM, et al. Seborrhoea - an indicator for poor clinical response in acne patients treated with antibiotics. Clin Exp Dermatol 1992;17:173-5
120. Margolis DJ, Bowe WP, Hoffstad O, Berlin JA. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol 2005;141(9):1132-6
121. Bowe WP, Hoffstad O, Margolis DJ. Upper respiratory tract infection in household contacts of acne patients. Dermatology (Basel, Switzerland) 2007;215(3):213-8
122. Lim DS, Murphy GM. High-level ultraviolet A photoprotection is needed to prevent doxycycline phototoxicity: lessons learned in East Timor. Br J Dermatol 2003;149:213-4
123. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996;134:695-5
124. Margolis DJ, Hoffstad O, Bilker W. Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. Br J Dermatol 2007;157(3):540-6
125. Sturkenboom MC, Meier CR, Jick H, et al. Minocycline and lupus-like syndrome in acne patients. Arch Intern Med 1999;159:493-7
126. Hughes BR, Murphy CE, Barnett J, Cunliffe WJ. Strategy of acne therapy with long-term antibiotics. Br J Dermatol 1989;121:623-8
127. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989;121(1):51-7
128. Ochsendorf FR, Richter T, Niemczyk UM, et al. Prospective detection of important bacterial pathogens in pyoderma and their in vitro antibiotic susceptibility. Hautarzt 2000;51(5):319-26
129. Plewig G, Gollnick H, Meigel W, Wokalek H. 13-Cis retinoic acid in the oral therapy of acne conglobata. Results of a multi-center study. Hautarzt 1981;32(12):634-46
130. Ward A, Brogden RN, Heel RC, et al. Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders. Drugs 1984;28(1):6-37
131. Leyden JJ, McGinley KJ, Foglia AN. Qualitative and quantitative changes in cutaneous bacteria associated with systemic isotretinoin therapy for acne conglobata. J Invest Dermatol 1986;86(4):390-3
132. Rawlings AV. The molecular biology of retinoids and their receptors. In: Acne and its Therapy. Webster G, et al. editors. New York: Informa Healthcare; 2007. p. 45-53
133. Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-Cis retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol 2006;126(10):2178-89
134. Karlsson T, Vahlquist A, Kedishvili N, Torma H. 13-Cis-retinoic acid competitively inhibits 3 alpha-hydroxysteroid oxidation
135. by retinol dehydrogenase RoDH-4: a mechanism for its and-androgenic effects in sebaceous glands? Biochem Biophys Res Commun 2003;303(1):273-8
136. Layton AM, Dreno B, Gollnick HP, Zouboulis CC. A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006;20(7):773-6
137. Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006;142(8):1016-22
138. Digiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol 2001;45(5):S176-82
139. Degitz K, Plewig G. Adjunctive treatments for acne therapy. J Dtsch Dermatol Ges 2005;3(2):92-6
140. Dreno B, Amblard P, Agache P, et al. Low doses of zinc gluconate for inflammatory acne. Acta Derm Venereol 1989;69(6):541-3
141. Hillstrom L, Pettersson L, Hellbe L, et al. Comparison of oral treatment with zinc sulphate and placebo in acne vulgaris. Br J Dermatol 1977;97(6):681-4
142. Dreno B, Moyse D, Alirezai M, et al. Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology (Basel, Switzerland) 2001;203(2):135-40
143. Michaelsson G, Juhlin L, Ljunghall K. A double-blind study of the effect of zinc and oxytetracycline in acne vulgaris. Br J Dermatol 1977;97(5):561-6
144. Cunliffe WJ, Burke B, Dodman B, Gould DJ. A double-blind trial of a zinc sulphate/citrate complex and tetracycline in the treatment of acne vulgaris. Br J Dermatol 1979;101(3):321-5
145. Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol 1961;73:367-70
146. Prendiville JS, Logan RA, Russell-Jones R. A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. Clin Exp Dermatol 1988;13(2):67-71
147. Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clin Exp Dermatol 1997;22(1):26-7
148. Hofer T, Itin PH. Acne inversa: a dapsone-sensitive dermatosis. Hautarzt 2001;52(10 Pt 2):989-92
149. Degitz K, Placzek M, Arnold B, et al. Congenital adrenal hyperplasia and acne in male patients. Br J Dermatol 2003;148(6):1263-6
150. Placzek M, Arnold B, Schmidt H, et al. Elevated 17-hydroxyprogesterone serum values in male patients with acne. J Am Acad Dermatol 2005;53(6):955-8
151. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003;46(Suppl 1):S7-16
152. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology (Basel, Switzerland) 2003;206(1):57-67
153. Zouboulis CC. Treatment of acne with antiandrogens - an evidence-based review. J Dtsch Dermatol Ges 2003;1:535-46
154. Farquhar C, Lee O, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev (Online) 2003;(4):CD000194
155. Muderris II, Bayram F, Guven M. Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol Endocrinol 2000;14(1):38-41
156. Thielitz A, Reinhold D, Vetter R, et al. Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation. J Invest Dermatol 2007;127(5):1042-51
157. Wiechers JW, Rawlings AV, Lindner N, Cunliffe WJ. Treating acne with octadecenedioic acid: mechanisms of action, skin delivery, and clinical results. In: Acne and its Therapy. Webster G, et al. editors. New York: Informa Healthcare; 2007. p. 137-54
158. Gold MH. Acne vulgaris: lasers, light sources and photodynamic therapy - an update 2007. Expert Rev Anti Infect Ther 2007;5(6):1059-69